We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

First-Ever Test Indicates Risk of Preeclampsia Months Before Symptoms Occur

By LabMedica International staff writers
Posted on 05 May 2022
Print article
Image: Mirvie RNA platform predicts pregnancy complications months before they occur (Photo courtesy of Mirvie)
Image: Mirvie RNA platform predicts pregnancy complications months before they occur (Photo courtesy of Mirvie)

Unexpected complications affect one in five pregnancies, with large economic costs and lifelong health consequences for expecting parents and babies. They often leave families in a state of crisis and are a primary driver of childhood morbidity and mortality, frequently resulting in neonatal intensive care for the baby’s survival. Pregnancy complications can double or even quadruple a mom’s lifetime risk of cardiovascular disease, regardless of how early the baby is born. Yet, women, expecting parents and doctors lack a reliable way to detect complications before symptoms appear. Now, the first test designed to indicate risk of preeclampsia months before symptoms occur has the potential to address a leading cause of maternal mortality that impacts millions of pregnancies each year.

The Mirvie Preeclampsia Test from Mirvie (South San Francisco, CA, USA) indicates a woman’s individualized risk of developing preeclampsia before symptoms occur. The test is powered by the proprietary Mirvie RNA platform, which is designed to predict the risk of unexpected complications by revealing the underlying biology of each pregnancy. The proprietary Mirvie RNA platform combines revolutionary analysis of tens of thousands of RNA messages from the baby, the placenta and the mom, with machine learning. The platform opens a new window into pregnancy health for expecting parents to act and their doctors to intervene before unexpected complications become a crisis.

Landmark research provides preliminary evidence that the Mirvie RNA platform can identify 75% of women who go on to develop preeclampsia months before symptoms occur. Additional research shows the platform can predict 76% of early preterm birth cases and identify distinct biological pathways driving its development. The Mirvie Preeclampsia Test is the first test for the early identification of preeclampsia risk months before any clinical presentation of symptoms to receive FDA Breakthrough Device designation. With this designation, Mirvie will continue ongoing clinical research to further validate the Mirvie Preeclampsia Test performance and improve the understanding of preeclampsia.

“Pregnancy health must become proactive, preventive, and personalized for the wellbeing of expecting parents and babies,” said Maneesh Jain, Ph.D., Co-Founder and CEO of Mirvie. “Ever-growing clinical evidence shows the Mirvie RNA platform is charting a new course to make that possible

“Prenatal care as we know it in the United States was first developed to primarily diagnose preeclampsia, yet these protocols have not changed in over fifty years,” said Eleni Tsigas, CEO of the Preeclampsia Foundation. “Moms and babies deserve more – there is an urgent need for innovation that not only identifies the risk of developing preeclampsia early, but also helps bring pregnancy health into the 21st century.”

Related Links:
Mirvie 

New
Gold Supplier
Chemistry Analyzer
BS-600M
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus
New
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
PCOCheck ELISA (CE)
New
Platinum Supplier
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.